Multiple Myeloma

CAR-T vs BCMA Bispecifics: Navigating Myeloma Treatment Decisions

Second-line treatment with belantamab mafodotin plus bortezomib/dexamethasone in patients with relapsed/refractory multiple myeloma is supported by findings from the phase 3 DREAMM-7 study.

Sagar Lonial, MD, FACP;Luciano Costa, MD, PhD;Cesar Rodriguez, MD;Donna Catamero, ANP-BC, OCN, CCRC

Key Takeaways on the Treatment of Patients With Relapsed/Refractory MM

Expert panelists review the complex decision-making process between CAR-T and BCMA bispecific therapies in the management of relapsed myeloma, discussing patient-specific factors and relative risks and benefits.

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD

Patient Scenario: Navigating Sequencing in Multiple Myeloma

The expert panel closes the discussion with key takeaways on the relapsed/refractory multiple myeloma treatment landscape.

Sagar Lonial, MD, FACP;Luciano Costa, MD, PhD;Cesar Rodriguez, MD;Donna Catamero, ANP-BC, OCN, CCRC

Treatment Decision-Making in Multiple Myeloma

A complex case study in multiple myeloma management, exploring treatment sequencing options for a patient with a long history of disease and multiple lines of therapy.

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD

Multiple Myeloma Experts Discuss Treatment Options and New Advances

Multiple myeloma–treating oncologists provide comprehensive insights on deciding between bispecific antibody monotherapy, combination therapy, and CAR T-cell therapy.

Experts in the field of multiple myeloma gathered to discuss treatment options, including bispecific antibodies, CAR T-cell therapy, and current and future FDA approvals for treatments.

Rina Lokaj

November 24th 2023

Experts in the field of multiple myeloma gathered to discuss treatment options, including bispecific antibodies, CAR T-cell therapy, and current and future FDA approvals for treatments.

Experts in the field of multiple myeloma gathered to discusses treatment options including bispecific antibodies CAR T-cell therapy, and the importance of collaborative decision-making across clinics.

CAR T-Cell Therapy Vs Bispecific Antibodies As Multiple Myeloma Treatment

Rina Lokaj

Managing Toxicity Following Bispecific Therapy in R/R Multiple Myeloma

Experts in the field of multiple myeloma gathered to discusses treatment options including bispecific antibodies CAR T-cell therapy, and the importance of collaborative decision-making across clinics.

$A panel of experts discusses the management of adverse effects including dysgeusia and infections among patients who received bispecific therapies for relapsed/refractory multiple myeloma in the context of a clinical case.$

Russ Conroy

Treatment Approaches for Frail Patients With RRMM

A panel of experts discusses the management of adverse effects including dysgeusia and infections among patients who received bispecific therapies for relapsed/refractory multiple myeloma in the context of a clinical case.

Carolina D. Schinke, MD;Joselle Cook, M.B.B.S;Luciano Costa, MD, PhD;Binod Dhakal, MD, MS

Toxicity Management in Patients With RRMM Receiving Bispecific Antibodies

Joselle Cook, M.B.B.S., explains that she believes that elderly patients with relapsed/refractory multiple myeloma can still use bispecific therapies, though more objective data on frailty is needed.

Carolina D. Schinke, MD;Joselle Cook, M.B.B.S;Luciano Costa, MD, PhD;Binod Dhakal, MD, MS

Mayo Clinic Reviews Outpatient Techniques for Monitoring Post CAR T-Cell Therapy

Drs Costa, Dhakal, and Cook discuss managing the unique toxicities of bispecific antibodies in patients with relapsed/refractory multiple myeloma such as infections requiring prophylaxis and supportive care, and quality-of-life complaints like taste changes and skin issues.

ONCOLOGY Staff

Multiple Myeloma: Optimizing ICANS and CRS Management

In a recent Training Academy, experts discussed how to incorporate bispecific antibodies into patients with multiple myeloma.

Sagar Lonial, MD, FACP;Luciano Costa, MD, PhD;Cesar Rodriguez, MD;Donna Catamero, ANP-BC, OCN, CCRC

Toxicities From GPRC5D-Targeting Therapies in Multiple Myeloma

Gain insight into strategies for monitoring for ICANS and CRS in myeloma treatment, including inpatient and outpatient administration, tocilizumab, dexamethasone, and impact on patient care.

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD

MM: Managing Toxicities From BCMA-Targeting Bispecific Antibodies

The panel continues their discussion on adverse effect management with a focus on GPRC5D-targeting bispecific antibodies in multiple myeloma.

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD

Managing AEs in Multiple Myeloma: Dosing and Prophylactic Strategies

Multiple myeloma specialists discuss the management of toxicities from BCMA-targeting bispecific antibodies.

Sagar Lonial, MD, FACP;Luciano Costa, MD, PhD;Cesar Rodriguez, MD;Donna Catamero, ANP-BC, OCN, CCRC

Cross Q&A: Role of Belantamab Mafodotin in MM

Key opinion leaders share their insight on managing adverse events in myeloma treatment, including dose adjustments and prophylactic strategies to improve outcomes and patient quality of life.

Craig Cole, MD, an expert on multiple myeloma, presenting slides

Andrew Kin, MD;Jeffrey Zonder, MD;Craig Cole, MD;Jay Yang, MD;Charles A. Schiffer, MD;Jack Khouri, MD;Faiz Anwer, MD;John Molina, MD, MEd;Moaath Mustafa Ali, MD, MPH

November 17th 2023

The panel discusses the efficacy of belantamab mafoditin and where the treatment fits in the multiple myeloma treatment landscape.

Treatment Recommendations for Relapsed Multiple Myeloma

ONCOLOGY Staff

November 16th 2023

Experts in the multiple myeloma space met to discuss the treatment and monitoring after bispecific antibodies.

Bispecific-Based Combinations Under Evaluation for Patients with RRMM

Carolina D. Schinke, MD;Joselle Cook, M.B.B.S;Luciano Costa, MD, PhD;Binod Dhakal, MD, MS

November 16th 2023

Joselle Cook, M.B.B.S., and Luciano Costa, MD, note promising trials investigating combination bispecific antibody therapies for patients with relapsed/refractory multiple myeloma.

Teclistamab plus Nirogacestat in RRMM: The MAJESTEC-2 Study

Carolina D. Schinke, MD;Joselle Cook, M.B.B.S;Luciano Costa, MD, PhD;Binod Dhakal, MD, MS

November 16th 2023

Drs Luciano Costa and Binod Dhakal discuss combining bispecific antibodies with gamma secretase inhibitors for the treatment of relapsed/refractory multiple myeloma, but trials show limited benefit and added toxicity; more promising are combinations with immunomodulators like isatuximab.

Adverse Events With Bispecific Therapy: Dysgeusia, Skin, and Nail Changes

Sagar Lonial, MD, FACP;Luciano Costa, MD, PhD;Cesar Rodriguez, MD;Donna Catamero, ANP-BC, OCN, CCRC

Managing Adverse Effects from Bispecific Antibodies in Multiple Myeloma

Overview of challenges in managing adverse events associated with bispecific therapy in multiple myeloma, including dysgeusia, skin toxicity, and nail changes patients may experience.

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD

Bispecific Therapies in Multiple Myeloma: Impact on Real-World Practice

Comprehensive insights on the management of adverse effects from bispecific antibodies in the treatment of multiple myeloma.

Sagar Lonial, MD, FACP;Luciano Costa, MD, PhD;Cesar Rodriguez, MD;Donna Catamero, ANP-BC, OCN, CCRC

Dosing Considerations for Bispecific Antibodies in MM

Experts share how the availability of three new bispecific therapies has transformed myeloma patient care, offering a lifeline to those previously without treatment options and showcasing positive responses in various patient populations.

Ajai Chari, MD;Brea C. Lipe, MD;Binod Dhakal, MD, MS;Jeffrey V. Matous, MD